JP Morgan Downgrades Phreesia to Underweight from Neutral
JP Morgan Downgrades Phreesia to Underweight, Announces $13 Price Target
Phreesia Sets Release Date for Fiscal Third Quarter 2027 Results
Phreesia: Q3 Must Prove That Growth Can Drive Higher Profitability
Barclays Maintains Equal-Weight on Phreesia, Raises Price Target to $11
Phreesia’s Michael Rasbury Named to Becker’s 2026 List of Rising Stars: Healthcare Leaders Under 40
Phreesia to Support Parkinson’s Disease Awareness and Research with The Michael J. Fox Foundation
Phreesia Named to TIME’s 2026 List of the World’s Top HealthTech Companies
Wall Street Splits on Phreesia (PHR) as Margins Improve but Growth Visibility Fades
Phreesia’s ProviderConnect Audiences are Now Available in the DeepIntent Audience Marketplace
Phreesia’s (PHR) Profit Turnaround Meets A Cash-Strapped Client Base
Phreesia (PHR) Q2 2027 Earnings Call Transcript
Raymond James Downgrades Phreesia to Market Perform
Phreesia, Inc. 2027 Q2 - Results - Earnings Call Presentation
DA Davidson Maintains Buy on Phreesia, Lowers Price Target to $13
Baird Maintains Neutral on Phreesia, Raises Price Target to $11
Phreesia Files Shelf Prospectus For Offering; Size Not Disclosed
Phreesia, Inc. Q2 2027 Earnings Call Summary
These Analysts Revise Their Forecasts On Phreesia After Q2 Results
RBC Capital Reiterates Outperform on Phreesia, Maintains $19 Price Target
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.